Tilray Brands Inc
TSX:TLRY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tilray Brands Inc
TSX:TLRY
|
US |
|
Y
|
Yuanbao Inc
NASDAQ:YB
|
CN |
|
Companhia Brasileira de Distribuicao SA
BOVESPA:PCAR3
|
BR |
|
OAR Resources Ltd
ASX:OAR
|
AU |
|
Ricardo PLC
LSE:RCDO
|
UK |
|
TV Tokyo Holdings Corp
TSE:9413
|
JP |
Tilray Brands Inc
Tilray Brands Inc. emerged on the cannabis scene as a formidable player, carving its niche in a highly volatile yet promising industry. Founded amidst the wave of cannabis legalization sweeping across North America, Tilray quickly became one of the first companies to go public on a major U.S. stock exchange. The company has built its reputation through strategic mergers and acquisitions, most notably its merger with Aphria in 2021, which positioned it as a global leader with comprehensive scale and operational efficiencies. Headquartered in Canada, Tilray has extended its reach with production and distribution facilities not only in the Americas but also across Europe and Australia, capitalizing on the burgeoning medical cannabis market and expanding adult-use sectors. Its array of products spans from dried cannabis flowers and oils to edibles and beverages, catering to diverse consumer needs.
Tilray's core business model hinges on a vertically integrated approach, which enables it to oversee the entire supply chain – from cultivation and processing to distribution and sales. This model not only enhances product consistency and quality control but also improves margins by reducing dependency on third-party suppliers. The company primarily generates revenue through its extensive portfolio of brand offerings, including medical-grade products for healthcare providers and recreational products for consumers. Additionally, it has embraced strategic partnerships and diversified into the consumer health and wellness space, venturing into hemp-based foods and alcoholic beverages. By leveraging its global infrastructure and brand strength, Tilray continues to navigate the evolving regulatory landscapes, aiming to capture a significant share of the cannabis industry's projected growth.
Tilray Brands Inc. emerged on the cannabis scene as a formidable player, carving its niche in a highly volatile yet promising industry. Founded amidst the wave of cannabis legalization sweeping across North America, Tilray quickly became one of the first companies to go public on a major U.S. stock exchange. The company has built its reputation through strategic mergers and acquisitions, most notably its merger with Aphria in 2021, which positioned it as a global leader with comprehensive scale and operational efficiencies. Headquartered in Canada, Tilray has extended its reach with production and distribution facilities not only in the Americas but also across Europe and Australia, capitalizing on the burgeoning medical cannabis market and expanding adult-use sectors. Its array of products spans from dried cannabis flowers and oils to edibles and beverages, catering to diverse consumer needs.
Tilray's core business model hinges on a vertically integrated approach, which enables it to oversee the entire supply chain – from cultivation and processing to distribution and sales. This model not only enhances product consistency and quality control but also improves margins by reducing dependency on third-party suppliers. The company primarily generates revenue through its extensive portfolio of brand offerings, including medical-grade products for healthcare providers and recreational products for consumers. Additionally, it has embraced strategic partnerships and diversified into the consumer health and wellness space, venturing into hemp-based foods and alcoholic beverages. By leveraging its global infrastructure and brand strength, Tilray continues to navigate the evolving regulatory landscapes, aiming to capture a significant share of the cannabis industry's projected growth.
Record quarter: Tilray reported third-quarter net revenue of $206.7 million, up 11% year over year, with gross profit of $55 million and adjusted EBITDA of $10.7 million, and it reaffirmed full-year adjusted EBITDA guidance of $62 million to $72 million.
International cannabis: The biggest growth engine was international cannabis, which reached $24.1 million in net sales, up 73% year over year, driven by higher volumes, stronger supply and continued expansion in markets like Germany.
Beer reset: Beverage revenue fell to $42.6 million, but management said Project 420 delivered $33 million of annualized cost savings and that the business is now at a trough margin level before the benefits of Carlsberg and BrewDog show up.
Strategic expansion: Tilray highlighted the BrewDog acquisition and Carlsberg partnership as major moves that expand its global beer platform and lift annualized revenue potential to about $1.2 billion.
Canada and Europe: Management said it is increasing cultivation capacity in Canada and improving yields in Europe to handle price pressure while improving supply consistency, especially in Germany.
Balance sheet: The company ended the quarter with $264.8 million in cash, restricted cash and marketable securities and a net cash position of $3.5 million, giving it flexibility to invest while staying disciplined.